Akero logo with white space 1.jpg
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022 16:05 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
June 27, 2022 07:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH
June 13, 2022 08:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
February 25, 2022 07:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero logo with white space 1.jpg
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
November 12, 2021 08:01 ET | Akero Therapeutics
Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks Histological...
Akero logo with white space 1.jpg
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021 07:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero logo with white space 1.jpg
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
October 19, 2021 16:15 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference
October 05, 2021 08:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero logo with white space 1.jpg
Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference
September 07, 2021 08:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Akero logo with white space 1.jpg
Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021 07:00 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...